Hemodialysis International · 2015 · 12 citations · 12 references
MedicineNephrologyOncologyMetastasisMolecular OncologyTumor ProgressionKidney CancerMetastatic Cancer ManagementMetastatic Disease TreatmentMetastatic Urologic CancerRenal Cell CarcinomaTargeted TherapyCombination Drug TherapyMetastatic Kidney CancerMetastatic Renal Cell Carcinoma TherapyRenal Failure ManagementRenal MalignancySorafenib TherapyTargeted Molecular TherapyTreatment Adverse Effects
A 62-year-old male patient with end-stage renal disease and metastatic renal cell carcinoma (RCC) was referred to our hospital. Sequential targeted therapy consisting of sorafenib, sunitinib, and everolimus was administered, but the patient's disease gradually progressed. Axitinib was subsequently administered at a decreased dose of 6 mg/day for 2 weeks, after which the dose was escalated to 10 mg/day. Axitinib therapy was maintained for a total of 6 months without severe adverse effects. Sequential molecularly targeted drug therapy including axitinib, with careful monitoring, is one possible treatment option for patients with metastatic RCC with renal impairment.
12
Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma
Bernard Escudier, Tim Eisen, Walter M. Stadler et al. · New England Journal of Medicine · 2007 · 4.8K citations · Full text
Medicine, Nephrology, Oncology +11